FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application from Prasco Laboratories to market Pioglitazone and Glimepiride as a fixed-dose combination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone and Glimepiride (pioglitazone and glimepiride)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)